Next Article in Journal
Ginseng Stem-Leaf Saponins in Combination with Selenium Promote the Immune Response in Neonatal Mice with Maternal Antibody
Next Article in Special Issue
Novel Inactivated Subtype B Avian Metapneumovirus Vaccine Induced Humoral and Cellular Immune Responses
Previous Article in Journal
Strategies to Improve Chimeric Antigen Receptor Therapies for Neuroblastoma
Previous Article in Special Issue
Combination of Innate Immune Modulators as Vaccine Adjuvants in Mice
Open AccessArticle

Repurposing of Miltefosine as an Adjuvant for Influenza Vaccine

1
State Key Laboratory for Emerging Infectious Diseases, Department of Microbiology, Carol Yu Centre for Infection, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Pokfulam, Hong Kong, China
2
Department of Medicine, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Pokfulam, Hong Kong, China
*
Author to whom correspondence should be addressed.
Vaccines 2020, 8(4), 754; https://doi.org/10.3390/vaccines8040754
Received: 18 November 2020 / Revised: 7 December 2020 / Accepted: 9 December 2020 / Published: 11 December 2020
We previously reported that topical imiquimod can improve the immunogenicity of the influenza vaccine. This study investigated another FDA-approved drug, miltefosine (MTF), as a vaccine adjuvant. Mice immunized with an influenza vaccine with or without MTF adjuvant were challenged by a lethal dose of influenza virus 3 or 7 days after vaccination. Survival, body weight, antibody response, histopathological changes, viral loads, cytokine levels, and T cell frequencies were compared. The MTF-adjuvanted vaccine (MTF-VAC) group had a significantly better survival rate than the vaccine-only (VAC) group, when administered 3 days (80% vs. 26.7%, p = 0.0063) or 7 days (96% vs. 65%, p = 0.0041) before influenza virus challenge. Lung damage was significantly ameliorated in the MTF-VAC group. Antibody response was significantly augmented in the MTF-VAC group against both homologous and heterologous influenza strains. There was a greater T follicular helper cell (TFH) response and an enhanced germinal center (GC) reaction in the MTF-VAC group. MTF-VAC also induced both TH1 and TH2 antigen-specific cytokine responses. MTF improved the efficacy of the influenza vaccine against homologous and heterologous viruses by improving the TFH and antibody responses. Miltefosine may also be used for other vaccines, including the upcoming vaccines for COVID-19. View Full-Text
Keywords: influenza vaccine; vaccine; adjuvant; TFH; miltefosine influenza vaccine; vaccine; adjuvant; TFH; miltefosine
Show Figures

Figure 1

MDPI and ACS Style

Lu, L.; Fong, C.H.-Y.; Zhang, A.J.; Wu, W.-L.; Li, I.C.; Lee, A.C.-Y.; Dissanayake, T.K.; Chen, L.; Hung, I.F.-N.; Chan, K.-H.; Chu, H.; Kok, K.-H.; Yuen, K.-Y.; To, K.K.-W. Repurposing of Miltefosine as an Adjuvant for Influenza Vaccine. Vaccines 2020, 8, 754. https://doi.org/10.3390/vaccines8040754

AMA Style

Lu L, Fong CH-Y, Zhang AJ, Wu W-L, Li IC, Lee AC-Y, Dissanayake TK, Chen L, Hung IF-N, Chan K-H, Chu H, Kok K-H, Yuen K-Y, To KK-W. Repurposing of Miltefosine as an Adjuvant for Influenza Vaccine. Vaccines. 2020; 8(4):754. https://doi.org/10.3390/vaccines8040754

Chicago/Turabian Style

Lu, Lu; Fong, Carol H.-Y.; Zhang, Anna J.; Wu, Wai-Lan; Li, Iris C.; Lee, Andrew C.-Y.; Dissanayake, Thrimendra K.; Chen, Linlei; Hung, Ivan F.-N.; Chan, Kwok-Hung; Chu, Hin; Kok, Kin-Hang; Yuen, Kwok-Yung; To, Kelvin K.-W. 2020. "Repurposing of Miltefosine as an Adjuvant for Influenza Vaccine" Vaccines 8, no. 4: 754. https://doi.org/10.3390/vaccines8040754

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Search more from Scilit
 
Search
Back to TopTop